SGC-CK2-1

SGC-CK2-1 is a highly potent and selective small molecule inhibitor of casein kinase 2 (CK2), a serine/threonine protein kinase involved in diverse cellular processes including cell survival, proliferation, and inflammation. It binds with equal potency to both catalytic subunits of CK2—CK2α (CSNK2A1) and CK2α' (CSNK2A2)—with nanomolar IC50 values. The compound is ATP competitive and demonstrates exceptional selectivity across the kinome. Developed as a chemical probe by the Structural Genomics Consortium (SGC), it has been used to dissect CK2 biology in various models, including cancer and neuroinflammation research. Unlike less selective CK2 inhibitors such as CX-4945, SGC-CK2-1 exhibits minimal off-target activity against other kinases at relevant concentrations[1][3][4][6][7].

Other names

N-(5-{[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino}-2-methylphenyl)propanamide